M
Magnus Tobiasson
Researcher at Karolinska University Hospital
Publications - 37
Citations - 1016
Magnus Tobiasson is an academic researcher from Karolinska University Hospital. The author has contributed to research in topics: Myelodysplastic syndromes & Medicine. The author has an hindex of 12, co-authored 23 publications receiving 638 citations. Previous affiliations of Magnus Tobiasson include Karolinska Institutet.
Papers
More filters
Journal ArticleDOI
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
Elsa Bernard,Yasuhito Nannya,Robert P. Hasserjian,Sean M. Devlin,Heinz Tuechler,Juan S. Medina-Martinez,Tetsuichi Yoshizato,Yusuke Shiozawa,Ryunosuke Saiki,Luca Malcovati,Max Levine,Juan E. Arango,Yangyu Zhou,Francesc Solé,Catherine Cargo,Detlef Haase,Maria Creignou,Ulrich Germing,Yanming Zhang,Gunes Gundem,Araxe Sarian,Arjan A. van de Loosdrecht,Martin Jädersten,Magnus Tobiasson,Olivier Kosmider,Matilde Y. Follo,Felicitas Thol,Ronald Feitosa Pinheiro,Valeria Santini,Ioannis Kotsianidis,Jacqueline Boultwood,Fabio P.S. Santos,Julie Schanz,Senji Kasahara,Takayuki Ishikawa,Hisashi Tsurumi,Akifumi Takaori-Kondo,Toru Kiguchi,Chantana Polprasert,John M. Bennett,Virginia M. Klimek,Michael R. Savona,Monika Belickova,Christina Ganster,Laura Palomo,Guillermo Sanz,Lionel Ades,Matteo G. Della Porta,Alexandra Smith,Yesenia Werner,Minal Patel,Agnes Viale,Katelynd Vanness,Donna Neuberg,Kristen E. Stevenson,Kamal Menghrajani,Kelly L. Bolton,Pierre Fenaux,Andrea Pellagatti,Uwe Platzbecker,Michael Heuser,Peter Valent,Shigeru Chiba,Yasushi Miyazaki,Carlo Finelli,Maria Teresa Voso,Lee Yung Shih,Michaela Fontenay,Joop H. Jansen,José Cervera,Yoshiko Atsuta,Norbert Gattermann,Benjamin L. Ebert,Rafael Bejar,Peter L. Greenberg,Mario Cazzola,Eva Hellström-Lindberg,Seishi Ogawa,Elli Papaemmanuil +78 more
TL;DR: Clinical sequencing across a large prospective cohort of patients with myelodysplasic syndrome uncovers distinct associations between the mono- and biallelic states of TP53 and clinical presentation.
Journal ArticleDOI
Myelodysplastic Syndromes Are Propagated by Rare and Distinct Human Cancer Stem Cells In Vivo
Petter S. Woll,Una Kjällquist,Onima Chowdhury,Helen Doolittle,David C. Wedge,Supat Thongjuea,Rikard Erlandsson,Mtakai Ngara,Kristina Anderson,Qiaolin Deng,Adam J. Mead,Laura Stenson,Alice Giustacchini,Sara Duarte,Eleni Giannoulatou,Stephen Taylor,Mohsen Karimi,Christian Scharenberg,Teresa Mortera-Blanco,Iain C. Macaulay,Sally Ann Clark,Ingunn Dybedal,Dag Josefsen,Pierre Fenaux,Peter Hokland,Mette Holm,Mario Cazzola,Luca Malcovati,Sudhir Tauro,David G. Bowen,Jacqueline Boultwood,Andrea Pellagatti,John E. Pimanda,Ashwin Unnikrishnan,Paresh Vyas,Gudrun Göhring,Brigitte Schlegelberger,Magnus Tobiasson,Gunnar Kvalheim,Stefan N. Constantinescu,Claus Nerlov,Lennart Nilsson,Peter J. Campbell,Rickard Sandberg,Elli Papaemmanuil,Eva Hellström-Lindberg,Sten Linnarsson,Sten Eirik W. Jacobsen,Sten Eirik W. Jacobsen +48 more
TL;DR: The existence of rare multipotent MDS stem cells (MDS-SCs), and their hierarchical relationship to lineage-restricted MDS progenitors, are established, with extensive implications for the targeting of the cells required and sufficient for MDS-propagation.
Journal ArticleDOI
Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic Syndromes
Ashwin Unnikrishnan,Elli Papaemmanuil,Elli Papaemmanuil,Dominik Beck,Dominik Beck,Nandan P. Deshpande,Arjun Verma,Arjun Verma,Ashu Kumari,Petter S. Woll,Petter S. Woll,Laura A. Richards,Kathy Knezevic,Vashe Chandrakanthan,Julie A. I. Thoms,Melinda L. Tursky,Yizhou Huang,Yizhou Huang,Zara Ali,Jake Olivier,Sally Galbraith,Austin G. Kulasekararaj,Magnus Tobiasson,Mohsen Karimi,Andrea Pellagatti,Sue Wilson,Robert Lindeman,Boris Young,Raj Ramakrishna,Christopher Arthur,Richard Stark,Philip Crispin,Jennifer Curnow,Pauline Warburton,Fernando Roncolato,Jacqueline Boultwood,Kevin Lynch,Sten Eirik W. Jacobsen,Sten Eirik W. Jacobsen,Ghulam J. Mufti,Eva Hellström-Lindberg,Marc R. Wilkins,Karen L. MacKenzie,Jason W. H. Wong,Peter J. Campbell,John E. Pimanda +45 more
TL;DR: It is shown that AZA responders have more hematopoietic progenitor cells (HPCs) in the cell cycle and, although AZA alters the sub-clonal contribution to different lineages, founder clones are not eliminated and continue to drive hematoiesis even in complete responders.
Journal ArticleDOI
Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial
Magnus Tobiasson,I Dybedahl,Mette Holm,Mohsen Karimi,L Brandefors,Hege Garelius,Michael Grövdal,I Högh-Dufva,Kirsten Grønbæk,Monika Jansson,Claus Werenberg Marcher,Lennart Nilsson,Astrid Olsnes Kittang,Anna Porwit,Leonie Saft,Lars Möllgård,Eva Hellström-Lindberg +16 more
TL;DR: It is concluded that Aza can induce TI in severely anemic MDS patients, but efficacy is limited, toxicity substantial and most responses of short duration, and this treatment cannot be generally recommended in lower-risk MDS.
Journal ArticleDOI
Myelodysplastic syndromes: moving towards personalized management
TL;DR: Treatment of higher-risk MDS is dominated by monotherapy with hypomethylating agents but novel combinations are currently being evaluated in clinical trials, and recent studies show increased cure rates due to better tools to target the malignant clone with less toxicity.